Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 9Phase 4 6Phase 1 5Phase NA 4Phase 1/2 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 1

Conditions

Papillomavirus Infections 5Uterine Cervical Neoplasms 3Condylomata Acuminata 2Vulvar Neoplasms 1Virus Diseases 1Vaginal Neoplasms 1Anus Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Papillomavirus Vaccines × Clear all
NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Shanghai Zerun Biotechnology Co.,Ltd

Phase 1 Completed
90 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05672966 2023-01-06

Phase I Clinical Trial of a Candidate HPV Vaccine

Wuhan BravoVax Co., Ltd.

Phase 1 Unknown
40 enrolled

Papillomavirus Infections

NCT03085381 2018-09-14

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

Shanghai Bovax Biotechnology Co., Ltd.

Phase 1 Completed
90 enrolled

Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡